SMYD family member 5Genealiases: NN8-4AG · RAI15 · RRG1 · ZMYND23
Q-omics provides the consensus-scored SMYD5 profile across patient tissues and cancer cell-line models. SMYD5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SMYD5 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SMYD5 protein abundance shows 20,944 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight LIHC, KIRC, and CCRCC as cancer lineages where SMYD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMYD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMYD5 survival associations across molecular data types. SMYD5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMYD5 RNA expression–survival associations across cancer types. High SMYD5 expression shows unfavorable associations in LIHC, ACC, KICH, BLCA and UCEC, but favorable associations in BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SMYD5 RNA expression.
This table summarizes SMYD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMYD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMYD5 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, STAD and BLCA. The KIRC box plot shows higher SMYD5 RNA expression in tumor versus normal tissue (log2 FC = +0.543, t-test p < 0.001).
This table shows molecular features associated with SMYD5 in patient tissues and cancer cell lines. In patient samples, SMYD5 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMYD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
